| 2026-03-03 Filed 2026-03-05 | Kozick Linda Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 4,956 | — | — | 0 | Direct (D) | No | F1, F2, F3, F4 - F1 Represents the annual grant of restricted stock units (RSUs) under the Issuer's Amended amp; Restated Non-Employee Director Compensation Policy, previously granted to the Reporting Person and reported on Form 4 dated February 2, 2026, which were scheduled to fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting.
- F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F3 Pursuant to the Merger Agreement, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the total number of Shares issuable in settlement of such RSU immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, which amount shall be paid in accordance with the Merger Agreement.
- F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
| Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Kozick Linda Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Director Stock Option (right to buy) — underlying Common Stock (2,083) — exercise price 16.32 | Disposed (D) | 2,083 | — | — | 0 | Direct (D) | No | F5, F2, F4, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Kozick Linda Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Director Stock Option (right to buy) — underlying Common Stock (521) — exercise price 49.44 | Disposed (D) | 521 | — | — | 0 | Direct (D) | No | F5, F2, F4, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Kozick Linda Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Director Stock Option (right to buy) — underlying Common Stock (521) — exercise price 108.96 | Disposed (D) | 521 | — | — | 0 | Direct (D) | No | F5, F2, F4, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Kozick Linda Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Director Stock Option (right to buy) — underlying Common Stock (1,917) — exercise price 96 | Disposed (D) | 1,917 | — | — | 0 | Direct (D) | No | F5, F2, F4, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Kozick Linda Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Director Stock Option (right to buy) — underlying Common Stock (417) — exercise price 96 | Disposed (D) | 417 | — | — | 0 | Direct (D) | No | F5, F2, F4, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Kozick Linda Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Director Stock Option (right to buy) — underlying Common Stock (938) — exercise price 226.16 | Disposed (D) | 938 | — | — | 0 | Direct (D) | No | F5, F2, F4, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Kozick Linda Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Director Stock Option (right to buy) — underlying Common Stock (938) — exercise price 154.40 | Disposed (D) | 938 | — | — | 0 | Direct (D) | No | F5, F2, F4, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Kozick Linda Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Director Stock Option (right to buy) — underlying Common Stock (1,063) — exercise price 109.12 | Disposed (D) | 1,063 | — | — | 0 | Direct (D) | No | F5, F2, F4, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Kozick Linda Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Director Stock Option (right to buy) — underlying Common Stock (1,618) — exercise price 167.44 | Disposed (D) | 1,618 | — | — | 0 | Direct (D) | No | F5, F2, F4, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Kozick Linda Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Director Stock Option (right to buy) — underlying Common Stock (4,561) — exercise price 37.04 | Disposed (D) | 4,561 | — | — | 0 | Direct (D) | No | F5, F2, F4, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Kozick Linda Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Director Stock Option (right to buy) — underlying Common Stock (32,229) — exercise price 7.44 | Disposed (D) | 32,229 | — | — | 0 | Direct (D) | No | F5, F2, F4, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001782274-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Wong Brian Russell Director · Officer: PRESIDENT AND CEO | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 64,102 | — | — | 0 | Direct (D) | No | F1, F2, F3, F4 - F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary
of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F3 The number of shares was adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F4 Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Offer Price.
| Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Wong Brian Russell Director · Officer: PRESIDENT AND CEO | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (25,000) — exercise price 49.44 | Disposed (D) | 25,000 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary
of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
| Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Wong Brian Russell Director · Officer: PRESIDENT AND CEO | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (8,334) — exercise price 50.40 | Disposed (D) | 8,334 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary
of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
| Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Wong Brian Russell Director · Officer: PRESIDENT AND CEO | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (10,417) — exercise price 12.56 | Disposed (D) | 10,417 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary
of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
| Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Wong Brian Russell Director · Officer: PRESIDENT AND CEO | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (7,500) — exercise price 12.56 | Disposed (D) | 7,500 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary
of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
| Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Wong Brian Russell Director · Officer: PRESIDENT AND CEO | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (18,750) — exercise price 12.56 | Disposed (D) | 18,750 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary
of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
| Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Wong Brian Russell Director · Officer: PRESIDENT AND CEO | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (37,500) — exercise price 12.56 | Disposed (D) | 37,500 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary
of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
| Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Wong Brian Russell Director · Officer: PRESIDENT AND CEO | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (31,250) — exercise price 12.56 | Disposed (D) | 31,250 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary
of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
| Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Wong Brian Russell Director · Officer: PRESIDENT AND CEO | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (34,375) — exercise price 12.56 | Disposed (D) | 34,375 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary
of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
| Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Wong Brian Russell Director · Officer: PRESIDENT AND CEO | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (218,250) — exercise price 9.12 | Disposed (D) | 218,250 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary
of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
| Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Wong Brian Russell Director · Officer: PRESIDENT AND CEO | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (371,875) — exercise price 7.43 | Disposed (D) | 371,875 | — | — | 265,625 | Direct (D) | No | F1, F2, F7, F8 - F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary
of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F7 Pursuant to the terms of the Merger Agreement, each stock option that is unvested as of immediately prior to the Effective Time and was granted after March 1, 2025 (a 2025 Option) was cancelled and converted into a cash-based award of Parent (a Converted Option), which shall entitle the holder thereof to receive an amount in cash equal to the Option Consideration (the Converted Option Consideration).
- F8 Each Converted Option (and the right to receive the Converted Option Consideration) shall be subject to the same terms and conditions (including vesting, forfeiture and acceleration provisions) that were applicable to the corresponding 2025 Option immediately prior to
the Effective Time; provided, that (i) the Converted Option Consideration shall vest and become payable 50% upon the date that closing occurs pursuant to the Merger Agreement (the Closing Date) and 50% upon the date that is nine months following the Closing Date and (ii) in the event that the holder of a Converted Option experiences an Involuntary Termination (as defined in the Merger Agreement) following the Closing Date but prior to the date that is nine months following the Closing Date, such holder's Converted Option
Consideration shall immediately vest and become payable without any further action on the part of Parent or any other person.
| Open filing 0001646110-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Lyons-Williams Lori Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 4,956 | — | — | 0 | Direct (D) | No | F1, F2, F3, F4 - F1 Represents the annual grant of restricted stock units (RSUs) under the Issuer's Amended amp; Restated Non-Employee Director Compensation Policy, previously granted to the Reporting Person and reported on Form 4 dated February 2, 2026, which were scheduled to fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting.
- F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F3 Pursuant to the Merger Agreement, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the total number of Shares issuable in settlement of such RSU immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, which amount shall be paid in accordance with the Merger Agreement.
- F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
| Open filing 0001693564-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Lyons-Williams Lori Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Director Stock Option (right to buy) — underlying Common Stock (2,813) — exercise price 306.24 | Disposed (D) | 2,813 | — | — | 0 | Direct (D) | No | F5, F2, F4, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001693564-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Lyons-Williams Lori Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Director Stock Option (right to buy) — underlying Common Stock (1,063) — exercise price 109.12 | Disposed (D) | 1,063 | — | — | 0 | Direct (D) | No | F5, F2, F4, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001693564-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Lyons-Williams Lori Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Director Stock Option (right to buy) — underlying Common Stock (1,618) — exercise price 167.44 | Disposed (D) | 1,618 | — | — | 0 | Direct (D) | No | F5, F2, F4, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001693564-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Lyons-Williams Lori Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Director Stock Option (right to buy) — underlying Common Stock (4,561) — exercise price 37.04 | Disposed (D) | 4,561 | — | — | 0 | Direct (D) | No | F5, F2, F4, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001693564-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Lyons-Williams Lori Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Director Stock Option (right to buy) — underlying Common Stock (32,229) — exercise price 7.44 | Disposed (D) | 32,229 | — | — | 0 | Direct (D) | No | F5, F2, F4, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001693564-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 4,648 | — | — | 0 | Direct (D) | No | F1, F2, F3, F4 - F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F3 The number of shares was adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F4 Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Offer Price.
| Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (1,225) — exercise price 49.44 | Disposed (D) | 1,225 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (1,035) — exercise price 50.40 | Disposed (D) | 1,035 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (3,125) — exercise price 108.96 | Disposed (D) | 3,125 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (2,500) — exercise price 12.56 | Disposed (D) | 2,500 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (6,250) — exercise price 12.56 | Disposed (D) | 6,250 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (3,876) — exercise price 12.56 | Disposed (D) | 6,876 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (7,000) — exercise price 12.56 | Disposed (D) | 7,000 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (9,375) — exercise price 12.56 | Disposed (D) | 9,375 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (64,375) — exercise price 9.12 | Disposed (D) | 64,375 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.
| Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Brockstedt Dirk G. Officer: CHIEF SCIENTIFIC OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (58,333) — exercise price 7.43 | Disposed (D) | 58,333 | — | — | 41,667 | Direct (D) | No | F1, F2, F7, F8 - F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F7 Pursuant to the terms of the Merger Agreement, each stock option that is unvested as of immediately prior to the Effective Time and was granted after March 1, 2025 (a 2025 Option) was cancelled and converted into a cash-based award of Parent (a Converted Option), which shall entitle the holder thereof to receive an amount in cash equal to the Option Consideration (the Converted Option Consideration).
- F8 Each Converted Option (and the right to receive the Converted Option Consideration) shall be subject to the same terms and conditions (including vesting, forfeiture and acceleration provisions) that were applicable to the corresponding 2025 Option immediately prior to the Effective Time; provided, that (i) the Converted Option Consideration shall vest and become payable 50% upon the date that closing occurs pursuant to the Merger Agreement (the Closing Date) and 50% upon the date that is nine months following the Closing Date and (ii) in the event that the holder of a Converted Option experiences an Involuntary Termination (as defined in the Merger Agreement) following the Closing Date but prior to the date that is nine months following the Closing Date, such holder's Converted Option Consideration shall immediately vest and become payable without any further action on the part of Parent or any other person.
| Open filing 0001635616-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Young Rodney KB Officer: CHIEF FINANCIAL OFFICER | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 3,304 | — | — | 0 | Direct (D) | No | F1, F2, F3, F4 - F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary
of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with
the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F3 The number of shares was adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F4 Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Offer Price.
| Open filing 0001337831-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Young Rodney KB Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (17,501) — exercise price 12.56 | Disposed (D) | 17,501 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary
of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with
the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
| Open filing 0001337831-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Young Rodney KB Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (7,500) — exercise price 12.56 | Disposed (D) | 7,500 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary
of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with
the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
| Open filing 0001337831-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Young Rodney KB Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (8,125) — exercise price 12.56 | Disposed (D) | 8,125 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary
of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with
the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
| Open filing 0001337831-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Young Rodney KB Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (8,501) — exercise price 12.56 | Disposed (D) | 8,501 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary
of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with
the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
| Open filing 0001337831-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Young Rodney KB Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (11,251) — exercise price 12.56 | Disposed (D) | 11,251 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary
of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with
the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
| Open filing 0001337831-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Young Rodney KB Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (80,250) — exercise price 9.12 | Disposed (D) | 80,250 | — | — | 0 | Direct (D) | No | F5, F1, F2, F6 - F5 The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.
- F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary
of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with
the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F6 Pursuant to the terms of the Merger Agreement, each stock option Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
| Open filing 0001337831-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Young Rodney KB Officer: CHIEF FINANCIAL OFFICER | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (69,271) — exercise price 7.43 | Disposed (D) | 69,271 | — | — | 49,479 | Direct (D) | No | F1, F2, F7, F8 - F1 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary
of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with
the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F2 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F7 Pursuant to the terms of the Merger Agreement, each stock option that is unvested as of immediately prior to the Effective Time and was granted after March 1, 2025 (a 2025 Option) was cancelled and converted into a cash-based award of Parent (a Converted Option), which shall entitle the holder thereof to receive an amount in cash equal to the Option Consideration (the Converted Option Consideration).
- F8 Each Converted Option (and the right to receive the Converted Option Consideration) shall be subject to the same terms and conditions (including vesting, forfeiture and acceleration provisions) that were applicable to the corresponding 2025 Option immediately prior to
the Effective Time; provided, that (i) the Converted Option Consideration shall vest and become payable 50% upon the date that closing occurs pursuant to the Merger Agreement (the Closing Date) and 50% upon the date that is nine months following the Closing Date and (ii) in the event that the holder of a Converted Option experiences an Involuntary Termination (as defined in the Merger Agreement) following the Closing Date but prior to the date that is nine months following the Closing Date, such holder's Converted Option
Consideration shall immediately vest and become payable without any further action on the part of Parent or any other person.
| Open filing 0001337831-26-000001 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Braunstein Scott Director | U Disposition pursuant to a tender of shares in a change of control transaction Common Stock | Disposed (D) | 4,956 | — | — | 0 | Direct (D) | No | F1, F2, F3, F4 - F1 Represents the annual grant of restricted stock units (RSUs) under the Issuer's Amended amp; Restated Non-Employee Director Compensation Policy, previously granted to the Reporting Person and reported on Form 4 dated February 2, 2026, which were scheduled to fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting.
- F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F3 Pursuant to the Merger Agreement, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the total number of Shares issuable in settlement of such RSU immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, which amount shall be paid in accordance with the Merger Agreement.
- F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
| Open filing 0001643875-26-000006 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-05 | Braunstein Scott Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Director Stock Option (right to buy) — underlying Common Stock (25,000) — exercise price 7.44 | Disposed (D) | 25,000 | — | — | 0 | Direct (D) | No | F2, F4, F5 - F2 The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the Merger Agreement) with GlaxoSmithKline LLC, a Delaware limited liability company (Parent), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (Purchaser) and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the Offer Price), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the Effective Time).
- F4 This Form 4 reports securities transacted pursuant to the Merger Agreement.
- F5 Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was less than Offer Price was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option.
| Open filing 0001643875-26-000006 Read from the filing’s XML Dispute this row |